Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Krishnansu Sujata Tewari"'
Autor:
Floor J. Backes, Lindsey B. Beffa, Caroline C. Billingsley, Michael J. Birrer, Kristin Bixel, Teresa K.L. Boitano, Wendy R. Brewster, Dana M. Chase, Shaina Bruce, Angelena Crown, Christina S. Chu, Daniel L. Clarke-Pearson, Robert A. Ross, Brian Crosland, Joshua G. Cohen, Robert L. Coleman, Paul A. DiSilvestro, Oliver Dorigo, Linda R. Duska, Ramez Nassef Eskander, Mary L. Gemignani, Camille Catherine Gunderson, Andrea R. Hagemann, Thomas J. Herzog, Travis R. Korenaga, Warner K. Huh, Lindsay Kuroki, Katherine Kurnit, Robert S. Mannel, L. Stewart Massad, Cara A. Mathews, David S. Miller, Bradley J. Monk, David G. Mutch, Rachita Nikam, JoAnn V. Pinkerton, Matthew Powell, Dominique L. Rash, Lisa M. Landrum, Kari L. Ring, Malte Renz, Brandon Roane, Stephen C. Rubin, Ritu Salani, Jane Satero, Anil K. Sood, John T. Soper, Elizabeth Christina Stock, C. James Sung, Krishnansu Sujata Tewari, Michael D. Toboni, Katherine Tucker, Joan L. Walker, Jaclyn A. Wall, Christina Washington, Lari B. Wenzel, Shannon N. Westin, Catheryn M. Yashar, William T. Creasman, Rosemary E. Zuna
Publikováno v:
DiSaia and Creasman Clinical Gynecologic Oncology ISBN: 9780323776844
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::59f2af7fb1962f9f8ad8f72cfeaa7346
https://doi.org/10.1016/b978-0-323-77684-4.00003-9
https://doi.org/10.1016/b978-0-323-77684-4.00003-9
Publikováno v:
DiSaia and Creasman Clinical Gynecologic Oncology ISBN: 9780323776844
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9c54a5167ccae1a83bbedb2a790cdf26
https://doi.org/10.1016/b978-0-323-77684-4.00021-0
https://doi.org/10.1016/b978-0-323-77684-4.00021-0
Publikováno v:
DiSaia and Creasman Clinical Gynecologic Oncology ISBN: 9780323776844
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::92b7708867e77d1ec511e14d90044774
https://doi.org/10.1016/b978-0-323-77684-4.00004-0
https://doi.org/10.1016/b978-0-323-77684-4.00004-0
Autor:
Krishnansu Sujata Tewari, Nicoletta Colombo, Bradley J. Monk, Coraline Dubot, M. Valeria Cáceres, Kosei Hasegawa, Ronnie Shapira-Frommer, Pamela Salman, Eduardo Yañez, Mahmut Gumus, Mivael Olivera Hurtado de Mendoza, Vanessa Samouëlian, Vincent Castonguay, Alexander Arkhipov, Cumhur Tekin, Kan Li, Sarper Toker, Stephen Michael Keefe, Domenica Lorusso
Publikováno v:
Journal of Clinical Oncology. 40:5506-5506
5506 Background: In KEYNOTE-826 (NCT03635567),pembrolizumab (pembro) + chemotherapy (chemo) ± bevacizumab (bev) provided statistically significant, clinically meaningful PFS and OS improvements in patients with persistent, recurrent, or metastatic c
Autor:
Richard T. Penson, Rebecca Christian Arend, Angeles Alvarez Secord, Antonio Casado Herraez, Thomas J. Herzog, Jonathan A. Ledermann, Kathleen N. Moore, Ronnie Shapira-Frommer, Krishnansu Sujata Tewari, Tamar Rachmilewitz Minei, Dror Harats, Shifra Fain Shmueli, Bradley J. Monk
Publikováno v:
Journal of Clinical Oncology. 40:TPS5606-TPS5606
TPS5606 Background: Ofranergene obadenovec (Ofra-vec, VB-111) is an anti-cancer gene based immune activator and targeted vascular disruptor. The dual mechanism of action triggers a broad antiangiogenic effect and induces of a tumor directed immune re
Autor:
Domenica Lorusso, Ignace Vergote, Roisin Eilish O'Cearbhaill, Anneke M. Westermann, Susana N. Banerjee, Els Van Nieuwenhuysen, David A Iglesias, Dearbhaile Catherine Collins, David Cibula, Kristine Madsen, Krishnansu Sujata Tewari, Sandro Pignata, Jean-Francois Baurain, Ingrid A. Boere, Hannelore denys, Camilla Mondrup Andreassen, Ibrahima Soumaoro, Shweta Jain, Christine N. Gennigens, Bradley J. Monk
Publikováno v:
Journal of Clinical Oncology. 40:5507-5507
5507 Background: TV monotherapy has received US accelerated approval for previously treated r/mCC with disease progression on or after chemotherapy based on clinically meaningful tumor response rate and duration of response (DOR) reported from the GO
Autor:
Kristin Leigh Bixel, Mario M. Leitao, Dana Meredith Chase, Allison Quick, Peter C Lim, Ramez Nassef Eskander, Walter H. Gotlieb, Salvatore LoCoco, Martin A Martino, Colleen McCormick, Tashanna K. N. Myers, Krishnansu Sujata Tewari, Brian M. Slomovitz, Joan L. Walker, Larry J. Copeland, Bradley J. Monk, Leslie M. Randall
Publikováno v:
Journal of Clinical Oncology. 40:TPS5605-TPS5605
TPS5605 Background: Minimally invasive surgery (MIS) is associated with improved perioperative safety outcomes, but, in 2018, the Laparoscopic Approach to Cervical Cancer (LACC) trial, a non-inferiority study comparing laparoscopic versus open radica
Autor:
Benoit You, Christopher Purdy, Elizabeth M. Swisher, Michael A. Bookman, Gini F. Fleming, Robert L. Coleman, Leslie M. Randall, Krishnansu Sujata Tewari, Bradley J. Monk, Robert S. Mannel, Joan L. Walker, Fabio Cappuccini, Larry J. Copeland, Mahvish Muzaffar, David Gardner Mutch, Andrea Elisabeth Wahner Hendrickson, Lainie P. Martin, Olivier Colomban, Robert Allen Burger
Publikováno v:
Journal of Clinical Oncology. 40:5553-5553
5553 Background: In patients with high-grade ovarian cancer in first-line setting, predictive factors of bevacizumab efficacy are needed, for selecting patients. In ICON-7 trial, a poor tumor intrisic chemosensitivity (defined by unfavorable modeled
Autor:
Rebecca Christian Arend, Bradley J. Monk, Thomas J. Herzog, Jonathan A. Ledermann, Kathleen N. Moore, Angeles Alvarez Secord, Ronnie Shapira-Frommer, Krishnansu Sujata Tewari, Tamar Rachmilewitz Minei, Dror Harats, Richard T. Penson
Publikováno v:
Journal of Clinical Oncology. 39:TPS5599-TPS5599
TPS5599 Background: Ofranergene obadenovec (VB-111) is a targeted anti-cancer gene therapy with a dual mechanism of action that includes a broad antiangiogenic effect and induction of a tumor directed immune response. A phase II trial in patients wit
Publikováno v:
Clinical advances in hematologyoncology : HO. 8(2)
Ongoing drug discovery and synergy in cytotoxic combinations have served as the dominant theme for clinical research in women with metastatic and recurrent cervical cancer. The results of the most recent phase III randomized clinical trials conducted